[1]
|
Eisenhofer, G., Huynh, T., Hiroi, M., et al. (2001) Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2, 297-311.
https://doi.org/10.1023/A:1011572617314
|
[2]
|
Eisenhofer, G., Rundquist, B., Aneman, A., et al. (1995) Regional Release and Removal of Catecholamines and Extraneuronal Metabolism to Metanephrines. The Journal of Clinical Endocrinology and Metabolism, 80, 3009-3017.
https://doi.org/10.1210/jcem.80.10.7559889
|
[3]
|
Niwa, M., Matsumoto, Y., Mouri, A., et al. (2011) Vulnerability in Early Life to Changes in the Rearing Environment Plays a Crucial Role in the Aetiopathology of Psychiatric Disorders. The International Journal of Neuropsychopharmacology, 14, 459-477. https://doi.org/10.1017/S1461145710001239
|
[4]
|
Eisenhofer, G., Kopin, I.J. and Goldstein, D.S. (2004) Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 56, 331-349. https://doi.org/10.1124/pr.56.3.1
|
[5]
|
Gu, Y.W., Poste, J., Kunal, M., et al. (2017) Cardiovascular Manifestations of Pheochromocytoma. Cardiology in Review, 25, 215-222. https://doi.org/10.1097/CRD.0000000000000141
|
[6]
|
Prejbisz, A., Lenders, J.W.M., Eisenhofer, G., et al. (2013) Mortality Associated with Phaeochromocytoma. Hormone and Metabolic Research, 45, 154. https://doi.org/10.1055/s-0032-1331217
|
[7]
|
Stolk, R.F., Bakx, C., Mulder, J., et al. (2013) Is the Excess Cardiovascular Morbidity in Pheochromocytoma Related to Blood Pressure or to Catecholamines? The Journal of Clinical Endocrinology & Metabolism, 98, 1100-1106.
https://doi.org/10.1210/jc.2012-3669
|
[8]
|
Lenders, J.W., Eisenhofer, G., Mannelli, M., et al. (2005) Phaeochromocytoma. The Lancet, 366, 665-675.
https://doi.org/10.1016/S0140-6736(05)67139-5
|
[9]
|
Berends, A.M.A., Buitenwerf, E., de Krijger, R.R., et al. (2018) Incidence of Pheochromocytoma and Sympathetic Paraganglioma in the Netherlands: A Nationwide Study and Systematic Review. European Journal of Internal Medicine, 51, 68-73. https://doi.org/10.1016/j.ejim.2018.01.015
|
[10]
|
Zuber, S.M., Kantorovich, V. and Pacak, K. (2011) Hypertension in Pheochromocytoma: Characteristics and Treatment. Endocrinology and Metabolism Clinics of North America, 40, 295-311. https://doi.org/10.1016/j.ecl.2011.02.002
|
[11]
|
Manger, W.M. (2009) The Protean Manifestations of Pheochromocytoma. Hormone and Metabolic Research, 41, 658.
https://doi.org/10.1055/s-0028-1128139
|
[12]
|
Li, X.S., Li, S. and Kellermann, G. (2016) Pre-Analytical and Analytical Validations and Clinical Applications of a Miniaturized, Simple and Cost-Effective Solid Phase Extraction Combined with LC-MS/MS for the Simultaneous Determination of Catecholamines and Metanephrines in Spot Urine Samples. Talanta, 159, 238-247.
https://doi.org/10.1016/j.talanta.2016.06.032
|
[13]
|
Pussard, E., Chaouch, A. and Said, T. (2014) Radioimmunoassay of Free Plasma Metanephrines for the Diagnosis of Catecholamine-Producing Tumors. Clinical Chemistry and Laboratory Medicine, 52, 437-444.
https://doi.org/10.1515/cclm-2013-0406
|
[14]
|
Eisenhofer, G., Peitzsch, M. and Mcwhinney, B.C. (2016) Impact of LC-MS/MS on the Laboratory Diagnosis of Catecholamine-Producing Tumors. TrAC Trends in Analytical Chemistry, 84, 106-116.
https://doi.org/10.1016/j.trac.2016.01.027
|
[15]
|
Davies, S.L. and Davison, A.S. (2019) Liquid Chromatography Tandem Mass Spectrometry for Plasma Metadrenalines. Clinica Chimica Acta, 495, 512-521. https://doi.org/10.1016/j.cca.2019.05.024
|
[16]
|
Eisenhofer, G. and Peitzsch, M. (2014) Laboratory Evaluation of Pheochromocytoma and Paraganglioma. Clinical Chemistry, 60, 1486-1499. https://doi.org/10.1373/clinchem.2014.224832
|
[17]
|
Eisenhofer, G., Lenders, J.W.M., Siegert, G., et al. (2012) Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma and Paraganglioma in Relation to Established Risk Factors of Tumour Size, Location and SDHB Mutation Status. European Journal of Cancer, 48, 1739-1749. https://doi.org/10.1016/j.ejca.2011.07.016
|
[18]
|
Willemsen, J.J., Ross, H.A., Lenders, J.W., et al. (2007) Stability of Urinary Fractionated Metanephrines and Catecholamines during Collection, Shipment, and Storage of Samples. Clinical Chemistry, 53, 268-272.
https://doi.org/10.1373/clinchem.2006.075218
|
[19]
|
Chen, H., Sippel, R.S., O’dorisio, M.S., et al. (2010) The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 39, 775-783.
https://doi.org/10.1097/MPA.0b013e3181ebb4f0
|
[20]
|
Berends, A., Eisenhofer, G., Fishbein, L., et al. (2019) Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers (Basel), 11, 1121. https://doi.org/10.3390/cancers11081121
|
[21]
|
Grouzmann, E., Centeno, C. and Eugster, P.J. (2018) Quantification of Vanillylmandelic Acid, Homovanillic Acid and 5-Hydroxyindoleacetic Acid in Urine Using a Dilute-and-Shoot and Ultra-High Pressure Liquid Chromatography Tandem Mass Spectrometry Method. Clinical Chemistry and Laboratory Medicine (CCLM), 56, 1533-1541.
https://doi.org/10.1515/cclm-2017-1120
|
[22]
|
Eisenhofer, G., Prejbisz, A., Peitzsch, M., et al. (2018) Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 64, 1646-1656. https://doi.org/10.1373/clinchem.2018.291369
|
[23]
|
Eisenhofer, G. and Lenders, J.W.M. (2018) Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. Clinical Chemistry, 64, 1780-1781. https://doi.org/10.1373/clinchem.2018.290791
|
[24]
|
Eisenhofer, G., Peitzsch, M., Kaden, D., et al. (2019) Reference Intervals for LC-MS/MS Measurements of Plasma Free, Urinary Free and Urinary Acid-Hydrolyzed Deconjugated Normetanephrine, Metanephrine and Methoxytyramine. Clinica Chimica Acta, 490, 46-54. https://doi.org/10.1016/j.cca.2018.12.019
|
[25]
|
Verly, I.R., van Kuilenburg, A.B., Abeling, N.G.G.M., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. https://doi.org/10.1016/j.ejca.2016.12.002
|
[26]
|
Verly, I.R.N., van Kuilenburg, A.B.P., Abeling, N.G.G.M., et al. (2018) 3-Methoxytyramine: An Independent Prognostic Biomarker That Associates with High-Risk Disease and Poor Clinical Outcome in Neuroblastoma Patients. European Journal of Cancer, 90, 102-110. https://doi.org/10.1016/j.ejca.2017.11.025
|
[27]
|
Patin, F., Crinière, L., Francia, T., et al. (2016) Low Specificity of Urinary 3-Methoxytyramine in Screening of Dopamine-Secreting Pheochromocytomas and Paragangliomas. Clinical Biochemistry, 49, 1205-1208.
https://doi.org/10.1016/j.clinbiochem.2016.05.008
|
[28]
|
Wang, J., Zhou, L., Lei, H., et al. (2017) Simultaneous Quantification of Amino Metabolites in Multiple Metabolic Pathways Using Ultra-High Performance Liquid Chromatography with Tandem-Mass Spectrometry. Scientific Reports, 7, 1416-1423. https://doi.org/10.1038/s41598-017-01435-7
|
[29]
|
Yu, S., Yin, Y., Li, Q., et al. (2019) Validation of an Improved Liquid Chromatography Tandem Mass Spectrometry Method for Rapid and Simultaneous Analysis of Plasma Catecholamine and Their Metabolites. Journal of Chromatography B, 1129, Article ID: 121805. https://doi.org/10.1016/j.jchromb.2019.121805
|
[30]
|
Verly, I.R., Van Kuilenburg, A.B., Abeling, N.G., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. https://doi.org/10.1016/j.ejca.2016.12.002
|
[31]
|
Rao, J.U., Engelke, U.F.H., Rodenburg, R.J.T., et al. (2013) Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 19, 3787-3795. https://doi.org/10.1158/1078-0432.CCR-12-3922
|
[32]
|
Verly, I.R.N., Leen, R., Meinsma, J.R., et al. (2019) Catecholamine Excretion Profiles Identify Clinical Subgroups of Neuroblastoma Patients. European Journal of Cancer, 111, 21-29. https://doi.org/10.1016/j.ejca.2019.01.014
|
[33]
|
Mamilla, D., Gonzales, M.K., Esler, M.D., et al. (2019) Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 48, 751-764. https://doi.org/10.1016/j.ecl.2019.08.004
|
[34]
|
Rodríguez-Morató, J., Pozo, Ó.J. and Marcos, J. (2018) Targeting Human Urinary Metabolome by LC-MS/MS: A Review. Bioanalysis, 10, 489-516. https://doi.org/10.4155/bio-2017-0285
|
[35]
|
Peitzsch, M., Mangelis, A., Eisenhofer, G., et al. (2019) Age-Specific Pediatric Reference Intervals for Plasma Free Normetanephrine, Metanephrine, 3-Methoxytyramine and 3-O-Methyldopa: Particular Importance for Early Infancy. Clinica Chimica Acta, 494, 100-105. https://doi.org/10.1016/j.cca.2019.03.1620
|